-
CKI 7 dihydrochloride: CK1 Assay Workflows
2026-09-22
Build cleaner biochemical and cell-based experiments with CKI 7 dihydrochloride, a selective Casein kinase 1 inhibitor for pathway dissection. This guide connects dosing, controls, Wnt and circadian assays, apoptosis readouts, and the MAPK10–KRT16 metastasis study without conflating distinct kinase systems.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-09-22
A 2024 bioRxiv preprint identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. RNA-seq and chromatin immunoprecipitation connect this effect to repetitive DNA, especially MIR elements near TERT intron 2, offering a mechanistic link between genome maintenance and telomerase regulation.
-
Dual HER2–VEGFR-2 Targeting in TNBC
2026-09-21
The 2026 reference study examines Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is phenotype-first evidence linking treatment with reduced invadopodia formation, cell proliferation, and two-dimensional tube formation, while also highlighting the difficulty of assigning direct receptor-specific mechanisms in a receptor-negative model.
-
PARP1/FAK/COL5A1 Drives Ovarian Cancer EMT
2026-09-21
The reference study establishes a cholesterol-resistant ovarian cancer model and identifies PARP1/FAK/COL5A1 signaling as a mechanistic link between chronic cholesterol exposure, EMT, and tumorigenesis. Its combination of long-term adaptation, pathway analysis, genetic depletion, pharmacologic perturbation, and in vitro and in vivo testing provides a useful framework for cancer biology research and FAK pathway interrogation.
-
KCNE4 Shapes Kv1.3 Blocker Pharmacology
2026-09-20
The reference study shows that the leukocyte auxiliary subunit KCNE4 changes how Kv1.3 responds to the intracellular blocker Psora 4 without measurably changing blocker affinity. By separating affinity from inhibition kinetics and comparing extracellular and intracellular channel blockers, the work provides a mechanistic framework for interpreting Kv1.3 pharmacology in immune-cell models.
-
Acetylcysteine in Patient-Specific Tumor Models
2026-09-19
Acetylcysteine can serve as a mechanistic redox perturbation in patient-derived organoid–fibroblast systems. This article explains how to interpret N-acetyl-L-cysteine responses in multicellular pancreatic cancer assays without confusing antioxidant activity with proof of chemosensitization.
-
SAG as a Translational Hedgehog Control Point
2026-09-18
SAG is more than a pathway-on reagent: it is a mechanistic control for separating ligand, Smoothened, and downstream Hedgehog biology. This thought-leadership guide connects SAG assay design with developmental modeling, stem cell maintenance research, tumorigenesis studies, and neuroregeneration while defining practical boundaries for translation.
-
APOL1 Evolution, Isoforms, and APOL3 Interaction
2026-09-18
The reference study integrates APOL1 molecular evolution, splice-isoform biology, and APOL3 interaction to refine explanations for variant-associated cellular injury. Its main practical implication is that APOL1 risk-variant experiments should preserve haplotype context, isoform identity, and protein-interaction state rather than treating APOL1 as a single uniform entity.
-
Renal K+ Channels in Septic Shock
2026-09-17
This study shows that renal potassium-channel blockade does not simply restore vasoconstrictor activity during sepsis: glibenclamide and iberiotoxin instead intensified agonist-associated reductions in renal blood flow in a time-dependent setting. Its paired isolated-kidney and in vivo design provides a useful framework for interpreting channel subtype effects, vascular reactivity, and the risks of combining channel blockers with pressor agents.
-
Pulsed Plasma Degradation of Sulfamonomethoxine
2026-09-17
The reference study shows that pulsed plasma discharge can degrade Sulfamonomethoxine (SMM) in aqueous solution with first-order kinetics and energy-dependent removal. Its central practical contribution is the combined assessment of degradation products and algal toxicity, revealing that treatment-generated hydrogen peroxide can remain hazardous even after the antibiotic declines.
-
BAP1, SLC7A11, and Disulfidptosis in Cancer
2026-09-16
The 2024 Oncogenesis study identifies BAP1 as a suppressor of glucose starvation-induced disulfidptosis, linking its regulation of SLC7A11 to cystine stress and NADPH availability. The findings clarify how BAP1 can oppose disulfidptosis while promoting other regulated cell-death programs, creating a framework for studying redox vulnerabilities in cancer cells.
-
Phenacetin as a Translational PK Benchmark
2026-09-16
A thought-leadership guide to using Phenacetin as a controlled pharmacokinetic research probe, with mechanistic context, solvent and stability guidance, safety boundaries, and a translational framework informed by PDK4 inhibitor development.
-
CasKAS: Genome-Wide CRISPR Specificity via ssDNA
2026-09-15
CasKAS profiles CRISPR specificity by chemically labeling the single-stranded DNA exposed when Cas9 or dCas9 forms an R-loop, enabling genome-wide detection of binding-associated sites and off-target activity. The approach is comparatively rapid and accessible because it does not depend exclusively on cleavage products, DNA repair outcomes, or ChIP-based occupancy measurements.
-
SCH772984 HCl: From ERK to TERT Control
2026-09-15
SCH772984 HCl is an ERK1/2 inhibitor that enables precise interrogation of MAPK signaling, drug resistance, and TERT regulation. This article connects kinase inhibition with chromatin-level assay design in human pluripotent stem cells and cancer models.
-
Pitavastatin (NK-104): In Vitro Workflow Guide
2026-09-14
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for investigating cholesterol biosynthesis in biochemical and cell-based assays. This guide supports controlled in vitro workflows and exploratory cardiovascular or atherosclerosis research, but the available dossier does not establish clinical, animal, or disease-model validation.